Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539412 | 0.86 | ALDH1A1 (0.76) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL28665987 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL9645453 | 0.85 | ALDH1A1 (0.81) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL15183729 | 0.85 | RAB9A (1.00) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL4724997 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL10943445 | 0.83 | RAB9A (0.88) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL5879030 | 0.83 | RAB9A (0.88) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL14855964 | 0.83 | SMN1; SMN2 (0.80) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL533802 | 0.82 | RAB9A (0.70) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL10939388 | 0.82 | SMN1; SMN2 (0.91) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| EP-0804440-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-0811008-B1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2003-10-01 | — | — | EP | disclosed |
| CN-1056374-C | Tricyclic diazepine vasopression antagonists | AMERICAN CYANAMID CO (US) | 2000-09-13 | — | — | CN | disclosed |
| US-5968930-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5968937-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5889001-A | TREATING CONDITIONS WHERE DECREASED VASOPRESSIN LEVELS ARE DESIRED AND DISEASES WITH EXCESS RENAL WATER REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5869483-A | KIDNEY DISEASES | AMERICAN CYANAMID COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| US-5624923-A | UROGENITAL AND CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | disclosed |
| US-5512563-A | TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| CN-1106812-A | Tricyclic diaza * vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1995-08-16 | — | — | CN | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | SMN1; SMN2 925/4885RAB9A 850/4885ALDH1A1 2561/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | SMN1; SMN2 925/4885RAB9A 850/4885ALDH1A1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.